DocDollars

Neuropace, Inc.

CA · United States · Reporting entity ID 100000010697

Total reported 2019–2025
$7.80M
#571 of 2,960 reporting companies — 0% of all reported industry payments
$2.00M in general payments across 7,153 records, plus $5.79M in research funding across 12,992 records.

How it breaks down

General payments $2,003,333
Research funding $5,794,082

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Neuropace, Inc. reported $7.80M to US doctors and teaching hospitals from 2019 to 2025, ranking #571 of 2,960 reporting companies. 74% of that was research funding and 26% general payments such as consulting, speaking, food and travel. 7,153 general payment records and 12,992 research records were filed.

Common questions about Neuropace, Inc.

How much has Neuropace, Inc. paid US doctors?

Neuropace, Inc. reported $7,797,415 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $2,003,333 in general payments, $5,794,082 in research funding.

How does Neuropace, Inc. rank among drug and device companies?

It ranks #571 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Neuropace, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.